阿替利珠单抗的专利布局及分析  

Patent Layout and Analysis of Atezolizumab

作　　者：赵天 李自财 黄璐[3,4,5] ZHAO Tian;LI Zicai;HUANG Lu(Guangdong Provincial Biotechnology Research Institute(Guangdong Provincial Laboratory Animals Monitoring Center),Guangzhou 510663;HIMMUC Information Technology(Guangzhou)Co.,Ltd.,Guangzhou 510670;School of Pharmacutical Sciences,Wuhan University,Wuhan 430072;School of Chemical Engineering and Pharmacy,Wuhan Institute of Technology,Wuhan 430205;Guangzhou BioBlue Technology Co.,Ltd.,Guangzhou 510200)

机构地区：[1]广东省生物技术研究院(广东省实验动物监测中心),广东广州510663 [2]天启黑马信息科技(广州)有限公司,广东广州510670 [3]武汉大学药学院,湖北武汉430072 [4]武汉工程大学化工与制药学院,湖北武汉430205 [5]广州市丹蓝生物科技有限公司,广东广州510200

出　　处：《中国医药工业杂志》2024年第10期1350-1358,共9页Chinese Journal of Pharmaceuticals

基　　金：国家社会科学基金项目——“专利到期药物仿制上市法律保障机制研究”(18BFX168)。

摘　　要：阿替利珠单抗作为一种新的PD-L1抑制剂药物,已成为肿瘤免疫治疗研究的热点之一。文章以阿替利珠单抗为研究对象,利用专利技术分析其相关专利申请状况,并重点从其技术主题和专利布局角度对阿替利珠单抗在中国的专利申请情况进行剖析,从而为国内研究机构和企业进行该药物研发和专利布局策略提供有效的参考和建议。Atezolizumab,as a new PD-L1 inhibitor drug,has become one of the hot spots in tumor immunotherapy research.This review takes atezolizumab as the research object,uses patent technology analysis to study the status of related patent applications,and focuses on the patent applications of atezolizumab in China from the perspective of its technical themes and patent layout,so as to provide some effective references and suggestions for domestic research institutions and enterprises in R&D and patent layout strategies of atezolizumab.

关 键 词：阿替利珠单抗 PD-L1抑制剂 肿瘤免疫治疗 专利技术分析 专利布局 

分 类 号：TQ464.9[化学工程—制药化工] R979.19[医药卫生—药品]